Longevity Edge

The Core Idea: Humanity is aging — and the companies solving that problem will be among the most valuable in the world over the next 20–30 years. "Longevity Edge" is built on a simple thesis: the intersection of biotech innovation, precision medicine, and medical technology is one of the most durable megatrends of our time. The portfolio targets three layers of this theme: Layer 1 – Pharma Giants with innovation pipelines Novo Nordisk and Eli Lilly represent the "picks and shovels" of modern medicine — dominant, profitable, and sitting at the frontier of obesity, diabetes, and aging-related disease research. They provide stability and consistent revenue. Layer 2 – Medtech & Surgical Innovation Intuitive Surgical and Stryker benefit from hospitals increasingly adopting robotic surgery and next-generation implants. These are high-margin businesses with strong recurring revenue models. Layer 3 – Precision Medicine & Diagnostics Illumina and Vertex Pharmaceuticals represent the cutting edge — genomics, gene editing, and rare disease treatment. Higher risk, but potentially transformative upside as personalized medicine scales globaly